1. Home
  2. ELS vs MDGL Comparison

ELS vs MDGL Comparison

Compare ELS & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ELS

Equity Lifestyle Properties Inc.

HOLD

Current Price

$63.87

Market Cap

13.2B

Sector

Real Estate

ML Signal

HOLD

Logo Madrigal Pharmaceuticals Inc.

MDGL

Madrigal Pharmaceuticals Inc.

HOLD

Current Price

$521.03

Market Cap

12.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELS
MDGL
Founded
1992
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2B
12.0B
IPO Year
1994
2005

Fundamental Metrics

Financial Performance
Metric
ELS
MDGL
Price
$63.87
$521.03
Analyst Decision
Buy
Strong Buy
Analyst Count
10
12
Target Price
$70.85
$674.45
AVG Volume (30 Days)
1.2M
349.8K
Earning Date
04-20-2026
04-30-2026
Dividend Yield
3.39%
N/A
EPS Growth
2.55
41.32
EPS
2.01
N/A
Revenue
$1,531,382,000.00
$180,133,000.00
Revenue This Year
$3.97
$58.39
Revenue Next Year
$4.69
$47.10
P/E Ratio
$31.87
N/A
Revenue Growth
0.34
N/A
52 Week Low
$57.63
$265.00
52 Week High
$69.00
$615.00

Technical Indicators

Market Signals
Indicator
ELS
MDGL
Relative Strength Index (RSI) 44.91 62.15
Support Level $58.56 $411.87
Resistance Level $68.73 $610.00
Average True Range (ATR) 1.00 26.99
MACD 0.10 3.75
Stochastic Oscillator 66.45 64.35

Price Performance

Historical Comparison
ELS
MDGL

About ELS Equity Lifestyle Properties Inc.

Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently has a portfolio of 455 properties across the US with a higher concentration in the Sunbelt; 38% of the company's properties are in Florida, 12% in Arizona, and 8% in California. Equity Lifestyle targets owning properties in attractive retirement destinations. More than 70% of the company's properties are either age-restricted or have an average resident age over 55.

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

Share on Social Networks: